The safety of Panretin gel has been assessed in clinical studies of more than 469 patients with AIDS- related KS, 439 of whom were treated with an alitretinoin concentration of 0.1%.
Panretin’ i geeli ohutust on hinnatud kliinilistes uuringutes rohkem kui 469 AIDS- iga seonduva KS- iga patsiendiga, kellest 439 raviti 0, 1% kontsentratsiooniga alitretinoiiniga.